Conflict of interest No conflicts of interest exist.
The influence of systemic therapy on the serum levels of IL-6 and IL-8 in pemphigus vulgaris
Article first published online: 2 NOV 2011
© 2011 The Authors. Journal of the European Academy of Dermatology and Venereology © 2011 European Academy of Dermatology and Venereology
Journal of the European Academy of Dermatology and Venereology
Volume 27, Issue 3, pages 387–390, March 2013
How to Cite
Mortazavi, H., Babaeijandaghi, F., Akbarzadeh, M., Rezaei, N., Amirzargar, A.A., Daneshpazhooh, M., Jalali, A. and Hallaji, Z. (2013), The influence of systemic therapy on the serum levels of IL-6 and IL-8 in pemphigus vulgaris. Journal of the European Academy of Dermatology and Venereology, 27: 387–390. doi: 10.1111/j.1468-3083.2011.04319.x
Funding sources The study was supported by Tehran University of Medical Sciences.
- Issue published online: 18 FEB 2013
- Article first published online: 2 NOV 2011
- Received: 5 May 2011; Accepted: 5 October 2011
Background The place of cell-mediated immunity and cytokines in the immunopathogenesis of pemphigus vulgaris (PV) has not been fully established.
Objective To assess the serum levels of pro-inflammatory cytokines, Interleukine-6 (IL-6) and Interleukine-8 (IL-8), in PV patients before and after therapy, to evaluate the influence of therapy on the serum cytokine levels.
Methods Sixty-six newly diagnosed PV patients enrolled into the study. The serum levels of IL-8 and IL-6 were measured in 66 and 64 patients, respectively. According to the extent of skin and mucosal involvement, the patients were divided into two groups namely mild and severe. The serum levels of cytokines were measured using enzyme-linked immunosorbent assay (ELISA) method before and after 4 weeks of prednisolone plus azathioprine therapy.
Results In 64 patients studied for the serum level of IL-6, the median IL-6 level was significantly decreased from 1.6 to 0.9 pg/mL by therapy (P-value = 0.001). Segregating the patients according to the severity of the disease, the serum level of IL-6 did not differ significantly by therapy in patients with a mild disease. However, in patients with a severe disease the median serum level of IL-6 decreased significantly from 1.8 to 0.9 pg/mL after therapy (P-value = 0.001). No significant changes were found in the IL-8 level by treatment.
Conclusion The significant decrease in the IL-6 level after therapy suggests that blocking of IL-6 could have therapeutic benefits for the treatment of PV, particularly in severe forms.